Press Releases Johnson & Johnson Swiss Exchange

Equities

JNJ

US4781601046

Delayed Swiss Exchange Other stock markets 11:36:28 2023-05-25 am EDT			5-day change	1st Jan Change
136 ^USD	-0.73%		-0.73%	-.--%

Jun. 20	Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease	MT
Jun. 20	Johnson & Johnson Submits Application to U.S. FDA Seek Approval of TREMFYA®? for the Treatment of Moderate to Severe Active Crohn's Disease	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Health Authority Warns of Brain Risks From Pseudoephedrine Medications	03:06am	AQ
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease	Jun. 20	PR
More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme	Jun. 20	BU
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction	Jun. 20	PR
Johnson & Johnson - Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer	Jun. 18	AQ
Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products	Jun. 17	BU
J&J commits five-year investment in Italian medicine manufacturing	Jun. 17	AQ
Johnson & Johnson - Late-breaking results show nipocalimab significantly improves Sjogren's disease activity in a Phase 2 study	Jun. 17	AQ
Johnson & Johnson - TALVEY demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma	Jun. 17	AQ
Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study	Jun. 15	PR
Johnson & Johnson : Findings from landmark RESONATE 2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first line chronic lymphocytic leukaemia treatment with up to 10 years follow up	Jun. 14	PU
Johnson & Johnson : Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed duration IMBRUVICA® (ibrutinib) plus venetoclax as first line treatment for patients with chronic lymphocytic leukaemia, including those with high risk disease	Jun. 14	PU
That's Stentertainment	Jun. 13	AQ
Johnson & Johnson : to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference Press Release	Jun. 12	PU
Talc Plaintiffs File Motion for Temporary Restraining Order to Limit Johnson & Johnson’s Use of Bankruptcy Strategy	Jun. 12	BU
Johnson & Johnson agrees to pay $700M to settle talcum lawsuit with dozens of states	Jun. 12	AQ
Johnson & Johnson : to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference Transcript	Jun. 11	PU
ERISA Group Health Plans – The New Target In Fee Cases	Jun. 11	AQ
Johnson & Johnson : DePuy Synthes Receives 510(k) FDA Clearance of the VELYS™ Robotic-Assisted Solution for Use in Unicompartmental Knee Arthroplasty Procedures	Jun. 07	PU
Johnson & Johnson Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy PREZCOBIX	Jun. 05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST